Tenaya Therapeutics Inc. (TNYA)
NASDAQ: TNYAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 11:00 AM ET
TNYA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $118.39M
- EPS (TTM)
- -$0.52
- Dividend yield
- None
- 52-week range
- 0.5211 – 2.35
- Day range
- 0.5211 – 0.5441
- Volume / Avg
- 996.11K / 2.26M
- Beta
- —
- Shares outstanding
- 224.23M
- Next earnings
- Nov 11, 2026
52-week range
TNYA stock today
On Oct 8, TNYA is trading at $0.528, shedding $0.0054 (1.01%), versus the S&P 500's 0.25% decline. At this level, TNYA sits near the bottom of its 52-week range of $0.5211 to $2.35: 77.5% below the high, set on Oct 10, 2025 and 1.3% above the low. TNYA is down 25.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 69.9%.
Tenaya Therapeutics has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful. Tenaya Therapeutics's next earnings report is expected on Nov 11, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Tenaya Therapeutics
Company profileTenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Faraz Ali M.B.A.
- Headquarters
- South San Francisco, CA
- Employees
- 70
- IPO year
- 2021
- Website
- tenayatherapeutics.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$3.20+506.06%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 11, 2026
Tenaya Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HUMAHumacyte Inc. | 0.4453 | -5.72% | $123.70M | vs TNYA |
| ENGNenGene Therapeutics Inc. | 1.69 | -3.44% | $112.92M | vs TNYA |
| LENZLENZ Therapeutics Inc. | 3.43 | -5.39% | $107.61M | vs TNYA |
| BDTXBlack Diamond Therapeutics Inc. | 1.80 | -1.91% | $102.86M | vs TNYA |
| ARMPArmata Pharmaceuticals Inc. | 3.68 | -3.41% | $136.83M | vs TNYA |
| OTLKOutlook Therapeutics Inc. | 0.5746 | -2.61% | $139.88M | vs TNYA |
| AVXLAnavex Life Sciences Corp. | 1.52 | -0.98% | $140.44M | vs TNYA |
| VYGRVoyager Therapeutics Inc. | 2.36 | -4.66% | $145.11M | vs TNYA |
Indexes, lists and sector
Tenaya Therapeutics stock FAQ
What is Tenaya Therapeutics's stock price today?
TNYA last traded at $0.528 as of Oct 8, 11:00 AM EDT, down 1.01% on the day. Prices are delayed at least 15 minutes.
When is Tenaya Therapeutics's next earnings date?
Tenaya Therapeutics is expected to report earnings on Wednesday, November 11, 2026.
Who is Tenaya Therapeutics's CEO?
Mr. Faraz Ali M.B.A. is the chief executive officer of Tenaya Therapeutics Inc., which has about 70 employees.
What is the TNYA 52-week high?
The 52-week high for TNYA is $2.35 and the 52-week low is $0.5211. The stock is currently 77.5% below its high.